Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemotherapy and the aging brain: how often does thinking slip?

NCT ID NCT07842679

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers at Assiut University are studying how common cognitive impairment is among adults aged 65 and older who receive chemotherapy for blood cancers such as leukemia or lymphoma. The study also examines whether thinking difficulties are linked to problems with everyday activities like dressing, cooking, or managing money. About 120 participants complete a standard thinking test and questionnaires about daily living skills. The study observes participants without giving them an experimental treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If researchers map how often thinking problems appear in this group, it could shape routine cognitive screening and support for older adults on chemotherapy.
What could go wrong
This is a single-timepoint observational study at one center, so it can show patterns but not cause and effect, and its findings may not apply to other hospitals or age groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Older adults aged 65 years or older with confirmed hematologic malignancies receiving chemotherapy at Assiut University Hospitals.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * \- Age 65 years or older * Confirmed diagnosis of hematologic malignancy * Currently receiving chemotherapy * Able to communicate and participate in cognitive assessment * Written informed consent Exclusion Criteria: * \- Previously diagnosed dementia before the diagnosis of malignancy * Delirium at the time of assessment * Severe visual or hearing impairment interfering with cognitive testing * History of major neurological disorders affecting cognition * Severe psychiatric illness affecting cognitive assessment * Critically ill patients unable to complete study assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chemotherapy effect are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity Cognitive Dysfunction hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chemotherapy effect Cognitive impairment Hematologic malignancies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.